New study tracks safety of adzynma for rare blood clot disorder
NCT ID NCT07353099
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the real-world safety of Adzynma, a lab-made protein, in people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare inherited blood disorder. Researchers will review medical records of about 50 children and adults to see how many develop allergic reactions or antibodies that stop the drug from working. The goal is to better understand long-term safety and effects during pregnancy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adzynma (lab-made ADAMTS13 protein)
What this could lead to
If successful, this study will provide crucial safety data on Adzynma, helping doctors better manage cTTP patients.
What could go wrong
This is an observational study, not a trial testing new effects. It only reviews existing medical records, so it cannot prove new benefits or risks beyond what is already known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AKH - Medizinische Universitaet Wien
RECRUITINGVienna, 1090, Austria
Contact
Contact Email: •••••@•••••
-
Klinikum Rechts der Isar der Technischen Universitaet Muenchen
NOT_YET_RECRUITINGMünchen, 81675, Germany
Contact
Contact
-
LMU Klinikum
NOT_YET_RECRUITINGMünchen, Germany
Contact
Contact Email: •••••@•••••
-
Universitaetsklinikum Jena
NOT_YET_RECRUITINGJena, 7743, Germany
Contact
Contact Email: •••••@•••••
-
Universitaetsklinikum Koeln
NOT_YET_RECRUITINGCologne, 50937, Germany
Contact
Contact Email: •••••@•••••
-
Universitaetsklinikum Leipzig
NOT_YET_RECRUITINGLeipzig, 4103, Germany
Contact Email: •••••@•••••
Contact
-
Universitatsklinikum Bonn
NOT_YET_RECRUITINGBonn, 53127, Germany
Contact
Contact Email: •••••@•••••